Quantcast

Latest Lorcaserin Stories

2010-03-08 15:00:00

SAN DIEGO, March 8, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Cowen and Company 30th Annual Health Care Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time) at the Boston Marriott Copley Place in Boston, Massachusetts. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company,...

2010-03-08 07:00:00

SAN DIEGO, March 8, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Friday, March 12, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss...

2010-02-26 07:00:00

SAN DIEGO, Feb. 26, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its...

2010-02-24 07:00:00

SAN DIEGO, Feb. 24, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA)...

2010-02-04 07:00:00

SAN DIEGO, Feb. 4, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery...

2009-12-23 15:05:00

SAN DIEGO, Dec. 23, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration. Merck made the decision to discontinue development of MK-1903 following evaluation...

2009-12-22 07:00:00

SAN DIEGO, Dec. 22, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials...

2009-12-10 18:00:00

SAN DIEGO, Dec. 10, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low. "Human abuse liability studies of the type done by Arena provide critical data to the FDA...

2009-11-24 07:00:00

SAN DIEGO, Nov. 24, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the New York Palace Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery...

2009-11-09 18:06:00

SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2009. Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related